AMR Action Fund

What AMR Action Fund does

The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, structured as a public-private partnership and operated by AMR Action Fund GP, S.à r.l. (Luxembourg). Launched in July 2020 by more than 20 leading biopharmaceutical companies under the auspices of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), in collaboration with the World Health Organization, the European Investment Bank, and Wellcome Trust, the Fund has over US$1 billion pledged with a stated objective of bringing 2 to 4 new antimicrobials to patients by 2030. It is headquartered in Boston, MA with a European office in Basel, Switzerland.

The Fund invests in small and mid-size, clinical-stage biotechnology companies developing treatments for WHO and CDC priority pathogens, spanning traditional small-molecule antibiotics, bacteriophage therapies, peptide therapeutics, and antibody-based immunotherapies. Its portfolio includes BioVersys, BiomX, Venatorx Pharmaceuticals, Vedanta Biosciences, Pattern Bioscience, Antabio, Utility Therapeutics, Elion Therapeutics, TenNor Therapeutics, F2G, Peptilogics, Centauri Therapeutics, and Adaptive Phage Therapeutics. Investments are typically executed through direct equity participation — leading or co-leading Series B/C and Series A extension rounds — and syndicated with global financial partners. An independent 9-member Scientific Advisory Board chaired by Dr. John H. Rex provides scientific evaluation of prospective investments.

The Fund's revenue model is venture-fund economics applied to a public-private partnership structure: management fees on committed/deployed capital, with the long-term economic thesis dependent on portfolio exits via M&A, IPOs, or product launches. In parallel with capital deployment, the Fund actively advocates for antimicrobial market reform — including pull-incentive mechanisms such as the PASTEUR Act and subscription-style reimbursement — and pursues policy partnerships (e.g., BEAM Alliance, Danish AMR Alliance, Novo Nordisk Foundation, UICC/BD Cancer and AMR Consortium) to create a sustainable commercial ecosystem. Notable portfolio milestones include the April 2024 FDA approval of pivmecillinam (PIVYA) via Utility Therapeutics and Alembic Pharmaceuticals' subsequent acquisition of Utility in July 2025.

Name

AMR Action Fund

Legal name

AMR Action Fund GP, S.à r.l.

Website

https://amractionfund.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, investing in clinical-stage biotechs developing treatments for WHO and CDC priority pathogens with over US$1 billion pledged from leading pharmaceutical companies and global health institutions.

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment

NAICS

Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital fund
• Antimicrobial therapeutics
• Biotech investment
• Antibiotic development
• Life sciences investing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Returns from Portfolio Companies: The AMR Action Fund is a venture capital fund that generates returns through equity investments in clinical-stage biotech companies developing antimicrobial therapeutics. Returns come from successful exits via M&A, IPOs, or product launches of portfolio companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics. It deploys equity capital (over $1 billion pledged) into clinical-stage biotech companies developing treatments for WHO and CDC priority pathogens, spanning traditional small-molecule compounds, bacteriophages, peptide therapeutics, and antibody-based therapies. The Fund also advocates for policy reforms such as subscription and pull-incentive models to create a sustainable market for new antibiotics.

Product overview

The AMR Action Fund is the world's largest venture capital fund dedicated exclusively to antimicrobial therapeutics, deploying approximately $1 billion to invest in clinical-stage biotech companies developing urgently needed treatments for WHO and CDC priority bacterial and fungal pathogens. The Fund operates as a single investment platform focused on enabling 2-4 new antimicrobials by 2030, investing in companies pursuing both traditional small-molecule compounds and innovative modalities including bacteriophage therapy, peptide therapeutics, and antibody-based immunotherapies. The portfolio spans 12+ companies addressing critical threats including carbapenem-resistant Acinetobacter baumannii (CRAB), C. difficile infections, prosthetic joint infections, and invasive fungal infections.

Differentiator

Problem solved

Functional benefit

Products and services

• AMR Action Fund Investment Portfolio Equity investments in small and mid-size clinical-stage biotech companies developing antimicrobial therapeutics for WHO and CDC priority pathogens, including both traditional small-molecule compounds and innovative modalities such as bacteriophages, peptide therapeutics, and antibody treatments.

Quantifiable outcome

• Aims to bring 2-4 new antimicrobials to patients by 2030
• +2 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered strategic and core.

• Cancer and AMR Consortium (with Union for International Cancer Control and BD)strategicStrategic or Co-development Partner · 1 June 2025The AMR Action Fund helped establish the Cancer and AMR Consortium in collaboration with the Union for International Cancer Control (UICC) and BD to address the threat AMR poses to cancer patients.
• Danish AMR AlliancestrategicStrategic or Co-development Partner · 8 April 2025Co-organized European Parliament event on antibiotics and health security together with BEAM Alliance, AMR Action Fund, and Novo Nordisk Foundation.
• BEAM AlliancestrategicStrategic or Co-development Partner · 8 April 2025Co-organized European Parliament event on antibiotics and health security together with Danish AMR Alliance, AMR Action Fund, and Novo Nordisk Foundation.
• World Health OrganizationcoreStrategic or Co-development Partner · 1 July 2020WHO collaborated with IFPMA and pharmaceutical companies to develop the concept for the AMR Action Fund. The Fund invests in treatments targeting WHO priority pathogens and aligns its scientific charter with WHO's AMR priorities.
• International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)coreStrategic or Co-development Partner · 1 July 2020IFPMA originated the concept for the AMR Action Fund in collaboration with member companies, WHO, European Investment Bank, and Wellcome Trust. IFPMA represents the R&D pharmaceutical industry internationally.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• CARB-X: Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator is a global non-profit partnership focused on accelerating antibacterial products to address drug-resistant infections. Directly comparable as another public-private AMR-focused funding entity with $480M+ committed, targeting the same portfolio-stage biotech companies and offering complementary non-dilutive and dilutive capital.
• Global Antibiotic R&D Partnership (GARDP): Swiss-based non-profit developing new antibiotic treatments and ensuring sustainable access. Directly comparable as a mission-driven public-private partnership developing and funding new antibiotics for priority pathogens; shares the AMR Action Fund's advocacy stance on access and stewardship principles.
• Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim (also an AMR Action Fund LP) with portfolio including Centauri Therapeutics. Comparable as a strategic corporate VC investing in early-stage biotech with therapeutic focus including infectious diseases, and overlaps directly on portfolio companies.
• Novo Ventures: Venture arm of Novo Holdings (associated with Novo Nordisk Foundation, an AMR Action Fund LP). Comparable as a large life sciences VC platform with significant biotech portfolio and global mandate; shares pharma/sovereign LP architecture and investment themes in biotech innovation.
• Novartis Venture Fund: Corporate VC arm of Novartis (also an AMR Action Fund LP), led previously by AMR Action Fund CEO Henry Skinner. Comparable as a strategic life sciences VC investing in early-stage therapeutics and providing syndication to AMR Action Fund portfolio companies.
• Wellcome Trust: Global charitable foundation focused on health research and a major AMR Action Fund LP ($66.8M). Comparable as a major AMR-focused philanthropic investor with their own direct investment programs in infectious disease therapeutics and a global advocacy mandate for pull incentives.
• SR One (GSK): Life sciences venture firm affiliated with GlaxoSmithKline (also an AMR Action Fund LP). Comparable as a strategic biotech VC investing in early-stage therapeutics including infectious disease, often co-investing in clinical-stage assets alongside other pharma-affiliated VCs.

Others

• BARDA (Biomedical Advanced Research and Development Authority): US HHS division providing funding for advanced development of medical countermeasures, including antibiotics targeting AMR threats. Comparable as a complementary non-dilutive funding source frequently used by AMR Action Fund portfolio companies to bridge development gaps.
• European Investment Bank: EU lending institution and AMR Action Fund LP ($24.1M, 2021). Comparable as a public financier of healthcare/biotech innovation including AMR therapeutics under Horizon Europe programs, often co-funding alongside the AMR Action Fund in European portfolio companies.

Emerging players

• Versant Ventures: Healthcare-focused VC with deep biotech franchise and history of launching clinical-stage companies including infectious disease plays. Comparable as a competing investor in clinical-stage biotech including potential AMR-relevant assets, frequently co-investing with corporate VC LPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=5U3k9ruszxI
• Xx.com/AMRActionFund
• LinkedInlinkedin.com/company/amr-action-fund

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMR Action Fund